Loading...
Market
Lenacapavir maintains 100% success rate in real-world by end of 2025?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
Clinical studies, health organization reports, and peer-reviewed publications
Story
Global Fund and PEPFAR to Distribute Lenacapavir, 100% Success Rate, to 2 Million People by 2026
Dec 17, 2024, 03:09 PM
A new long-acting preventive drug for HIV, known as Lenacapavir, is set to be distributed in the world's poorest countries by late 2025 or early 2026. This initiative is part of a coordinated effort by the Global Fund and PEPFAR, aiming to reach 2 million people with the drug, which has shown 100% success in trials. Health officials believe that this drug could significantly reduce global HIV infections and accelerate the fight against the virus by 2030.
View original story
Similar markets
More effective in men • 25%
More effective in gender-diverse individuals • 25%
Equally effective in both groups • 25%
Insufficient data for conclusion • 25%
Yes • 50%
No • 50%
Approved in USA only • 25%
Approved in EU only • 25%
Approved in both USA and EU • 25%
Not approved in USA or EU • 25%
0 • 25%
1 • 25%
2 • 25%
3 or more • 25%
